<DOC>
	<DOC>NCT02123381</DOC>
	<brief_summary>This study aim to investigate Changes in tumor tissue and serum biomarkers before and after cetuximab combined with preoperative radiotherapy in locally advanced thoracic middle-lower segment esophageal squamous cell carcinoma.We want to find one or more effective biomarkers to predict and evaluate the patients who will be benefit from cetuximab combined with preoperative radiotherapy.</brief_summary>
	<brief_title>Changes in Tumor Tissue and Serum Biomarkers Before and After Cetuximab Combined With Preoperative Radiotherapy in Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Squamous Cell</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>(1)18 to 65 years old,male or female (2)Pathologically or cytologically proven thoracic middlelower esophageal squamous cell carcinoma; (3)clinical stage II or stage III; (4)Primary tumors can be measured; (5)Karnofsky score &gt;70; (6)Estimated life expectancy of at least 12 weeks; (7)reproductive age women should ensure that before entering the study period contraception; (8)Hemoglobin≥90.0g/dL,white blood cell count（WBC）≥ 4000 cells/mm³,Platelet count≥100,000 cells/mm³; (9)Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) &lt; 2.5 times upper limit of normal,bilirubin normal; (10)Creatinine normal OR creatinine clearance ≥ 60 mL/min; (11)Patients have good compliance to treatment and followup of acceptance; (12)Forced expiratory volume in one second（FEV1） ≥ 1.5 litre or ≥ 75% of the reference value; (13)Considered operable (i.e. appropriate organ functions and ability to undergo general anesthesia); (14)No severe or uncontrolled cardiovascular disease; (15)No active uncontrolled infection; 1. Patient who have distant metastasis 2. The primary tumor or lymph node already received surgical treatment (except for biopsy); 3. Patient who received radiotherapy for primary tumor or lymph node; 4. Patient who received the the epidermal growth factor targeted therapy; 5. Patient who received chemotherapy or immunotherapy; 6. Patient who suffered from other malignant tumor; 7. Epidermal growth factor receptor（EGFR）mutation（）; 8. Patient who have taken other drug test within 1 month; 9. Pregnant woman or Lactating Women and Women in productive age who refuse to take contraception in observation period; 10. Subject with a severe allergic history or idiosyncratic; 11. Subject with severe pulmonary and cardiopathic disease history; Refuse or incapable to sign the informed consent form of participating this trial; 12. Drug abuse or alcohol addicted; 13. Subject with a Personality or psychiatric diseases, people with no legal; capacity or people with limited capacity for civil conduct;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>tumor tissue and serum biomarkers</keyword>
	<keyword>cetuximab</keyword>
	<keyword>preoperative radiotherapy</keyword>
	<keyword>esophageal squamous cell carcinoma</keyword>
</DOC>